Antibiotic resistance in prevotella species isolated from patients with cystic fibrosis

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 10, 2013, Pages 2369-2374

  Sherrard, Laura J ^a   Graham, Kathryn A ^a   McGrath, Stef J ^a   McIlreavey, Leanne ^a   Hatch, Joseph ^b   Muhlebach, Marianne S ^b   Wolfgang, Matthew C ^b   Gilpin, Deirdre F ^a   Elborn, J Stuart ^a,c   Schneiders, Thamarai ^c   Tunney, Michael M ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

lactamase production; Anaerobic bacteria; Antimicrobial susceptibility

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CEFTAZIDIME; CHLORAMPHENICOL; CLINDAMYCIN; DOXYCYCLINE; MEROPENEM; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; TETRACYCLINE; TOBRAMYCIN;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM ISOLATION; CONTROLLED STUDY; HUMAN; LUNG FIBROSIS; LUNG INFECTION; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; PRESCRIPTION; PREVOTELLA; PSEUDOMONAS AERUGINOSA; STREPTOCOCCUS PNEUMONIAE; UNITED KINGDOM;

ANAEROBIC BACTERIA; ANTIMICROBIAL SUSCEPTIBILITY; Β-LACTAMASE PRODUCTION;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; BACTEROIDACEAE INFECTIONS; BETA-LACTAMASES; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; DRUG RESISTANCE, BACTERIAL; FEMALE; GREAT BRITAIN; HUMANS; INFANT; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PREVOTELLA; YOUNG ADULT;

EID: 84888793937     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt191     Document Type: Article

References (19)

1. Zaura E, Keijser BJ, Huse SM et al. Defining the healthy 'core microbiome' of oral microbial communities. BMC Microbiol 2009; 9: 259.
2. Charlson ES, Bittinger K, Haas AR et al. Topographical continuity of bacterial populations in the healthy human respiratory tract. Am J Respir Crit Care Med 2011; 184: 957-63.
3. Tunney MM, Field TR, Moriarty TF et al. Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am J Respir Crit Care Med 2008; 177: 995-1001.
4. Tunney MM, Klem ER, Fodor AA et al. Use of culture and molecular analysis to determine the effect of antibiotic treatment on microbial community diversity and abundance during exacerbation in patients with cystic fibrosis. Thorax 2011; 66: 579-84.
5. Harris JK, DeGroote MA, Sagel SD et al. Molecular identification ofbacteria in bronchoalveolar lavage fluid from children with cystic fibrosis. Proc Natl Acad Sci USA 2007; 104: 20529-33.
6. Bittar F, Richet H, Dubus JC et al. Molecular detection of multipleemerging pathogens in sputa from cystic fibrosis patients. PLoS ONE 2008; 3: e2908.
7. Zhao J, Schloss PD, Kalikin LM et al. Decade-long bacterial community dynamics in cystic fibrosis airways. Proc Natl Acad Sci USA 2012; 109: 5809-14.
8. Fodor AA, Klem ER, Gilpin DF et al. The adult cystic fibrosis airway microbiota is stable over time and infection type, and highly resilient to antibiotic treatment of exacerbations. PLoS ONE 2012; 7: e45001.
9. Elborn JS, Tunney MM. Macrolides and bronchiectasis: clinical benefit with a resistance price. JAMA 2013; 309: 1295-6.
10. Field TR, Sibley CD, Parkins MD et al. The genus Prevotella in cystic fibrosis airways. Anaerobe 2010; 16: 337-44.
11. Jamal W, Shahin M, Rotimi VO. Surveillance and trends of antimicrobial resistance among clinical isolates of anaerobes in Kuwait hospitals from 2002 to 2007. Anaerobe 2010; 16: 1-5.
12. Citron DM, Goldstein EJ, Merriam CV et al. Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents. J Clin Microbiol 2007; 45: 2819-28.
13. Liu CY, Huang YT, Liao CH et al. Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. Antimicrob Agents Chemother 2008; 52: 3161-8.
14. Ardila CM, Granada MI, Guzman IC. Antibiotic resistance of subgingival species in chronic periodontitis patients. J Periodontal Res 2010; 45: 557-63.
15. Lakhssassi N, Elhajoui N, Lodter JP et al. Antimicrobial susceptibility variation of 50 anaerobic periopathogens in aggressive periodontitis: an interindividual variability study. Oral Microbiol Immunol 2005; 20: 244-52.
16. Grinwis ME, Sibley CD, Parkins MD et al. Macrolide and clindamycin resistance in Streptococcus milleri group isolates from the airways of cystic fibrosis patients. Antimicrob Agents Chemother 2010; 54: 2823-9.
17. Saiman L, Anstead M, Mayer-Hamblett N et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2010; 303: 1707-15.
18. Albert RK, Connett J, Bailey WC et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011; 365: 689-98.
19. Budhani RK, Struthers JK. Interaction of Streptococcus pneumoniae and Moraxella catarrhalis: investigation of the indirect pathogenic role of b-lactamase-producing moraxellae by use of a continuousculture biofilm system. Antimicrob Agents Chemother 1998; 42: 2521-6.